Trump Says Politics Could Be Holding Back Covid Plasma Treatment

The transcript discusses the potential use of convalescent plasma to treat COVID-19, highlighting the FDA's hesitation to issue an emergency use authorization due to insufficient evidence. It touches on possible political influences delaying approval and emphasizes the need for swift action to prevent further deaths. The speaker mentions hearing positive efficacy rates and urges the White House to expedite the process.

Why did the FDA pause the emergency use authorization for convalescent plasma?

• Due to a lack of evidence as per NIH officials

• Due to public protests

• Because it was already approved

• Because of a successful trial

What potential reason is suggested for the delay in approving convalescent plasma?

• Political motivations

• Technical issues

• Lack of funding

• Public opinion

What success rate is mentioned for convalescent plasma?

• 20%

• 10%

• Over 50%

• 75%

What role does the White House play in the approval process of convalescent plasma?

• Conducting clinical trials

• Encouraging quick action from NIH and FDA

• Opposing the treatment

• Providing financial support

What is the speaker's main concern regarding the delay in treatment approval?

• People dying

• Increased costs

• Lack of public awareness

• Insufficient media coverage